Immuron (STU:ANWA) Other Long-Term Liabilities : €0.08 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Immuron Other Long-Term Liabilities?

Immuron's other long-term liabilities for the quarter that ended in Dec. 2023 was €0.08 Mil.

Immuron's quarterly other long-term liabilities increased from Dec. 2022 (€-0.00 Mil) to Jun. 2023 (€0.00 Mil) and increased from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.08 Mil).

Immuron's annual other long-term liabilities increased from Jun. 2021 (€0.00 Mil) to Jun. 2022 (€0.00 Mil) but then declined from Jun. 2022 (€0.00 Mil) to Jun. 2023 (€0.00 Mil).

Immuron Other Long-Term Liabilities Historical Data

The historical data trend for Immuron's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Other Long-Term Liabilities Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial												-	-	-	-	-

Immuron Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Immuron Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Immuron's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (STU:ANWA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines